Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients

Sponsor
Jannie Bisgaard Stæhr (Other)
Overall Status
Completed
CT.gov ID
NCT04633850
Collaborator
(none)
45
1
7.6
5.9

Study Details

Study Description

Brief Summary

To investigate the effect of intercostal blockade with and without adjuvants.

Detailed Description

Video-assisted thoracoscopic surgery (VATS) is a minimally invasive routine procedure. It's less invasive than thoracotomy but postoperative pain is still a problem.

At Aalborg University Hospital, intercostal blockades with bupivacaine is used as standard pain treatment for patients undergoing VATS. Adding adjuvants to the blockades may prolong the effect.

The aim of this study is to investigate if intercostal nerve blockade with adjuvants (intravenous (IV) dexamethasone) will result in better pain management.

The primary plan was to evaluate the effect of adding IV dexamethasone and perineural adrenaline, but due to adverse effects, adrenaline was first reduced and later removed from the intervention (amendment protocol N-20200040 approved by the Ethics Committee of Northern Jutland on February 2nd 2021).

Study Design

Study Type:
Observational
Actual Enrollment :
45 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients: A Before and After Study
Actual Study Start Date :
Sep 8, 2020
Actual Primary Completion Date :
Apr 28, 2021
Actual Study Completion Date :
Apr 28, 2021

Arms and Interventions

Arm Intervention/Treatment
Before implementation

Perineural bupivacaine without adjuvants.

Drug: Bupivacain
Bupivacaine dose according to weight. <60 kg: Total dose 100mg 60-90kg: Total dose 150mg >90kg: Total dose 200mg Given once at the end of surgery.

After implementation

Perineural bupivacaine with intravenous dexamethasone.

Drug: Dexamethasone
Intravenous dexamethasone 8 mg. Given once at the end of surgery.

Outcome Measures

Primary Outcome Measures

  1. Total equipotent dose of opioids [24 hours]

    Sum of equipotent opioid doses during the first 24 hours after surgery

Secondary Outcome Measures

  1. Time to first administration of opioids after surgery [48 hours]

    In hours and minuts

  2. Numerical rating scale score [24 hours]

    Pain score reported by the patient after surgery from 0 (no pain) to 10 (worst imaginable pain) in whole numbers.

  3. Time for full mobilization [Through study completion, an average of 1 week]

    The total time for full mobilization (walk with support)

  4. Total dose of non-opioid analgesics [24 hours]

    Sum of non-opioid doses during the first 24 hours after surgery

  5. The need for pain medication at discharge [At discharge from hospital, an average of 1 week]

    The need for pain medication at discharge (all forms, type, dose)

  6. Postoperative complication (Empyema) [At discharge from hospital, an average of 1 week]

    Empyema (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)

  7. Postoperative complication (Air leakage) [At discharge from hospital, an average of 1 week]

    Air leakage (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)

  8. Postoperative complication (Reoperation) [At discharge from hospital, an average of 1 week]

    Reoperation (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)

  9. Postoperative complication (Pneumonia) [At discharge from hospital, an average of 1 week]

    Pneumonia (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)

  10. Postoperative complication (Drainage of pleural effusion) [At discharge from hospital, an average of 1 week]

    Pleural effusion (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)

  11. Postoperative complication (Oyxgen therapy) [At discharge from hospital, an average of 1 week]

    The need for supplemental oxygen therapy and need for mechanical ventilation (yes/no) as complication to the surgery described in the patients journal at discharge (epicrisis)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

° Consecutive adult patients over 18 years of age scheduled to undergo VATS because of verified/suspected lung cancer.

Exclusion Criteria:
  • Inability to understand verbal and written information.

  • Preexisting chronic pain condition.

  • Preoperative daily treatment with pain medication (Non-opioids, opioids, gabapentin/pregabalin).

  • Previous thoracic surgery.

  • Previous chemotherapy due to thoracic malignancy and / or radiation therapy. to the thorax.

  • Pregnant women.

  • Autoimmune neuromuscular diseases (sclerosis, peripheral neuromuscular disorders). General muscle weakness or atrophy.

  • Hypersensitivity, allergy or intolerance to dexamethasone, bupivacaine or adrenaline.

  • Preoperative epidural anaesthesia.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aalborg University Hospital Aalborg Region Of Northern Jutland Denmark 9000

Sponsors and Collaborators

  • Jannie Bisgaard Stæhr

Investigators

  • Principal Investigator: Jannie Bisgaard Stæhr, PhD, MD, Department of Anaesthesia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jannie Bisgaard Stæhr, MD PhD, Aalborg University Hospital
ClinicalTrials.gov Identifier:
NCT04633850
Other Study ID Numbers:
  • Smerter efter VATS
First Posted:
Nov 18, 2020
Last Update Posted:
Jul 1, 2021
Last Verified:
Jun 1, 2021
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 1, 2021